Pharmaceutical Reshoring — Rebuilding France’s Biomanufacturing Sovereignty

The COVID-19 pandemic delivered a brutal reckoning for France’s pharmaceutical industry. A nation that once stood alongside the United States, Germany, and Switzerland as a global pharmaceutical powerhouse discovered it could not manufacture sufficient quantities of paracetamol, surgical masks, or diagnostic reagents without Chinese and Indian suppliers. The humiliation was compounded when France failed to develop a successful domestic COVID-19 vaccine — Sanofi’s protein-based candidate arrived more than a year behind Pfizer/BioNTech and Moderna, and the Institut Pasteur abandoned its mRNA and measles-vector vaccine programs entirely. These failures catalyzed a fundamental reassessment of France’s pharmaceutical sovereignty, resulting in a €3.8 billion commitment under France 2030 to rebuild domestic biomanufacturing capacity and position France at the frontier of next-generation therapies.

The Erosion of French Pharma Leadership

France’s pharmaceutical decline is one of the most striking examples of industrial hollowing-out in a developed economy. In the early 2000s, France was Europe’s largest pharmaceutical producer by value, with Sanofi, Servier, Ipsen, and a dense ecosystem of biotechnology firms generating over €50 billion in annual production. French pharmaceutical exports exceeded imports by approximately €7 billion, and the sector employed 100,000 workers in manufacturing alone.

By 2020, the picture had transformed dramatically. France had fallen to fourth in European pharmaceutical production, behind Germany, Switzerland, and Italy. The pharmaceutical trade surplus had collapsed to approximately €1 billion, and manufacturing employment had declined to approximately 70,000. Most critically, France had lost its position in the highest-value segments of pharmaceutical manufacturing — biological medicines (biotherapies) and advanced therapy medicinal products (ATMPs) — where production increasingly concentrated in Ireland, Switzerland, Singapore, and the United States.

The causes of this decline were multifaceted. France’s pharmaceutical taxation framework — including the “contribution sur les dépenses de promotion des médicaments” and the “clause de sauvegarde” that clawed back revenues above negotiated thresholds — created a disincentive for capital investment in French production facilities. The country’s complex regulatory environment, including the Comité Économique des Produits de Santé (CEPS) pricing negotiations that frequently resulted in lower reimbursement rates than Germany or the UK, discouraged pharmaceutical companies from launching new products in France first. Most damagingly, Sanofi’s strategic decision in the 2010s to offshore active pharmaceutical ingredient (API) production to India and China — reducing costs but creating the supply chain vulnerabilities exposed during COVID-19 — removed a critical mass of manufacturing capability.

The France 2030 Health Innovation Strategy

The €3.8 billion health innovation allocation within France 2030 addresses pharmaceutical reshoring through four main channels: biotherapy manufacturing capacity, infectious disease preparedness, digital health transformation, and workforce development.

Biotherapy and Bioproduction (€1.4 billion): The largest allocation targets the construction and expansion of biological medicine manufacturing facilities in France. Biotherapies — including monoclonal antibodies, gene therapies, cell therapies, and mRNA-based medicines — represent the fastest-growing segment of the global pharmaceutical market, projected to exceed $500 billion by 2030. France’s share of European bioproduction was approximately 5% in 2021, compared to 25% for Ireland and 20% for Germany. The France 2030 objective is to increase this share to 12% by 2030.

Key investments include Sanofi’s €1.5 billion “EVO” (Evolutive) bioproduction facility in Neuville-sur-Saône, near Lyon, which represents the largest single pharmaceutical manufacturing investment in France in two decades. The Sanofi EVO plant uses a revolutionary modular, digitally-integrated design that enables rapid reconfiguration between different biological products — a lesson learned from the pandemic, when traditional fixed-format production facilities could not pivot quickly to new products. The facility can produce multiple biological products simultaneously, with production changeover times reduced from months to weeks through single-use bioreactor technology and continuous manufacturing processes.

Additional bioproduction investments include Servier’s €200 million expansion of its oncology manufacturing facility in Gidy (Loiret), the creation of a national mRNA manufacturing platform at the Établissement Français du Sang (EFS) in collaboration with CureVac, and investments in gene therapy viral vector production at Genethon’s facilities in Évry-Courcouronnes. The Genethon investment is particularly strategic: the institute, originally founded by the AFM-Téléthon patient association, has developed manufacturing capabilities for adeno-associated virus (AAV) vectors used in gene therapies for rare diseases, a technology segment where France has differentiated expertise.

Infectious Disease Preparedness (€0.9 billion): The pandemic exposed catastrophic gaps in France’s infectious disease response infrastructure. The France 2030 allocation funds the creation of the Agence de l’Innovation en Santé (AIS), a new agency modeled on the US BARDA (Biomedical Advanced Research and Development Authority) designed to accelerate the development and procurement of medical countermeasures. The AIS has a mandate to maintain a portfolio of at least 10 advanced medical countermeasure programs at any time, ensuring that France is never again caught without domestic vaccine or therapeutic development capabilities.

Investments also target the modernization of BSL-3 and BSL-4 laboratory infrastructure (including the Jean Mérieux-Inserm BSL-4 laboratory in Lyon, one of only a handful of maximum containment facilities in Europe), the creation of a national pandemic simulation and forecasting capability, and the establishment of emergency-use pharmaceutical manufacturing surge capacity that can be activated within weeks of a public health declaration.

Digital Health and Health Data (€0.8 billion): Recognizing that modern pharmaceutical development is increasingly data-driven, France 2030 invests in the Health Data Hub (HDH), a national health data platform aggregating anonymized records from the French healthcare system (which covers 67 million residents). The HDH provides pharmaceutical companies and researchers with one of the world’s largest real-world evidence datasets, potentially accelerating clinical development timelines and reducing costs. The €800 million allocation also funds telemedicine infrastructure, AI-assisted diagnostic platforms, and the digitization of France’s hospital information systems.

Workforce and Training (€0.7 billion): The pharmaceutical reshoring effort requires significant human capital investment. France currently graduates approximately 3,000 pharmacists annually and 200 specialized bioproduction engineers — the latter figure entirely inadequate for the planned manufacturing expansion. The France 2030 training program targets doubling bioproduction engineering graduates by 2028 through new programs at the Université de Strasbourg, Université Claude Bernard Lyon 1, and the creation of a dedicated bioproduction training center (the “Campus Biotech Production”) at the Genopole biotech cluster in Évry.

Sanofi’s Strategic Transformation

Sanofi’s evolution is central to France’s pharmaceutical reshoring narrative. Under CEO Paul Hudson (appointed 2019), Sanofi has undergone a fundamental strategic reorientation, divesting lower-margin business lines (including the consumer healthcare division, spun off as Opella in 2024) and concentrating investment on immunology, oncology, and rare diseases — high-value therapeutic areas dominated by biological medicines.

Sanofi’s French manufacturing footprint has been strategically consolidated and upgraded. The company operates 14 production sites in France, employing approximately 15,000 manufacturing workers. Key facilities include the Neuville-sur-Saône EVO bioproduction plant, the Val-de-Reuil vaccine production complex (one of the world’s largest vaccine manufacturing sites, producing over 1 billion vaccine doses annually), the Vitry-sur-Seine research and development campus (Sanofi’s global R&D headquarters, employing 3,500 scientists), and the Sisteron API synthesis plant (which produces active ingredients for cardiovascular and diabetes medicines).

Sanofi’s R&D pipeline increasingly focuses on biological medicines that can be manufactured at French facilities. The company’s blockbuster immunology drug Dupixent (dupilumab), which generated €13.2 billion in global sales in 2025, is manufactured partly at French sites. Sanofi’s next-generation pipeline includes several gene therapy and bispecific antibody candidates that would leverage the new bioproduction infrastructure being built under the France 2030 framework.

However, Sanofi’s relationship with the French state remains complex. The company’s decision to sell its consumer health division to an American private equity consortium (CD&R) triggered political backlash, with French lawmakers accusing Sanofi of “dismantling a national champion.” The government’s use of foreign investment screening powers (Article L151-3 of the Monetary and Financial Code) to impose conditions on the Opella sale — including employment guarantees and continued French production of paracetamol — illustrated the tensions between corporate strategy and national sovereignty objectives.

The API Reshoring Challenge

Active pharmaceutical ingredient (API) manufacturing represents the most strategically sensitive dimension of pharmaceutical reshoring. Approximately 80% of APIs consumed in Europe are manufactured in China and India, a concentration that creates supply chain risks ranging from quality control failures (China’s Zhejiang Hisun pharmaceutical contamination incidents) to geopolitically-motivated export restrictions.

France’s API reshoring strategy operates on two tracks. First, selective domestic API production for the most critical molecules: the government has identified 50 “essential medicines” (including paracetamol, amoxicillin, corticosteroids, and several oncology agents) for which domestic or European API sourcing is being mandated through public procurement requirements. The Seqens Group (a French specialty pharmaceutical company) has invested €100 million in expanding API production at its Villeneuve-la-Garenne and Couterne plants, specifically targeting reshored paracetamol and ibuprofen API production.

Second, diversification of supply chains away from single-source dependencies: rather than attempting full API self-sufficiency (which would be economically unrealistic for the majority of molecules), France is supporting multi-source qualification programs that ensure at least two geographically diversified suppliers for each critical API. The ANSM (Agence Nationale de Sécurité du Médicament), France’s pharmaceutical regulator, has accelerated approval processes for alternative API suppliers, reducing qualification timelines from an average of 18 months to 9 months for designated critical molecules.

European Coordination and Competition

France’s pharmaceutical reshoring occurs within a competitive European landscape. Ireland, with its 12.5% corporate tax rate and streamlined regulatory environment, continues to attract the lion’s share of biopharmaceutical manufacturing investment in Europe. Switzerland, Germany, and Denmark all maintain significant pharmaceutical manufacturing ecosystems that compete with France for investment.

The EU Pharmaceutical Strategy for Europe (adopted 2020, legislative proposals 2023) provides a framework for continental coordination but has limited direct instruments for directing manufacturing investment. The European Health Emergency Preparedness and Response Authority (HERA), established in 2021 with a €6 billion budget, complements national efforts by maintaining strategic medical countermeasure stockpiles and coordinating pandemic preparedness R&D.

France has advocated for stronger European instruments to incentivize domestic pharmaceutical manufacturing, including proposals for “Made in Europe” preferences in hospital procurement and regulatory fast-tracking for drugs manufactured within the EU. These proposals have encountered resistance from free-trade-oriented member states (Netherlands, Denmark, Sweden) and from the pharmaceutical industry itself, which argues that supply chain disruptions are best addressed through diversification rather than reshoring mandates.

Clinical Trial Competitiveness

Beyond manufacturing, France is working to restore its attractiveness as a clinical trial destination — a critical factor in pharmaceutical investment decisions, since companies tend to manufacture where they conduct clinical development. France’s share of global clinical trials declined from approximately 8% in 2005 to 4% in 2020, displaced by lower-cost Eastern European sites and more efficient US and UK regulatory environments.

The France 2030 response includes the creation of a national clinical trial acceleration platform, reducing trial approval timelines from an average of 85 days to a target of 45 days. The Agence de l’Innovation en Santé has been given authority to fast-track trial approvals for priority therapeutic areas. Hospital-based clinical research infrastructure has been upgraded through €500 million in investments in 30 designated “Centres de Recherche Clinique de Référence” across France’s teaching hospitals (CHU).

Early results are encouraging: France attracted 12% more clinical trial applications in 2025 than in 2023, with particular growth in oncology, gene therapy, and rare disease studies. The density and quality of France’s healthcare system — with 67 million patients covered by a single-payer system and comprehensive electronic health records — provides structural advantages for real-world evidence generation and large-scale clinical studies.

Assessment and Outlook

France’s pharmaceutical reshoring strategy addresses a genuine sovereignty gap with a comprehensive, well-funded approach. The €3.8 billion France 2030 allocation, combined with private sector investment exceeding €5 billion (led by Sanofi’s facility modernization program), represents the largest pharmaceutical industrial policy initiative in French history.

The strategy’s emphasis on biotherapies and advanced manufacturing technologies (continuous production, single-use bioreactors, digitally-integrated facilities) positions France in the highest-growth segments of the pharmaceutical market. The focus on bioproduction workforce development addresses the most binding constraint on manufacturing expansion. The creation of BARDA-equivalent capabilities through the Agence de l’Innovation en Santé provides institutional infrastructure for pandemic preparedness that was conspicuously absent in 2020.

However, significant execution risks remain. France’s pharmaceutical taxation and pricing framework — while improved through recent LFSS (Loi de Financement de la Sécurité Sociale) reforms — continues to create disincentives for certain categories of pharmaceutical investment. The tension between Sanofi’s global corporate strategy and French national sovereignty objectives, illustrated by the Opella controversy, highlights the difficulty of using a multinational corporation as the primary vehicle for national industrial policy. Most fundamentally, the question of whether reshored French pharmaceutical manufacturing can achieve cost competitiveness with Asian production — where labor costs are 60-70% lower and environmental and safety regulations are less stringent — remains unresolved.

The pharmaceutical reshoring initiative will be judged ultimately by whether it restores France’s ability to produce critical medicines domestically, attracts sustained private investment without permanent subsidy dependency, and positions the French pharmaceutical ecosystem at the technological frontier of biotherapy manufacturing. The infrastructure being built under France 2030 creates the necessary conditions; translating those conditions into competitive, sustainable pharmaceutical production will require sustained policy commitment extending well beyond the 2030 horizon.